VI.2 Elements for a public summary

VI.2.1 Overview of disease epidemiology

Pain is one of the common reasons for a platient to take medicine. Moderate or severe plain can remain for short or long duration, sometimes, for weeks, months or even years. Long term pain can be due to some accidental injury or there may be an ongoing pain due to swelling of joints (arthritis), but some people suffer with long term pain in the absence of any past injury or body damage. It has been judged that one in five adults suffers from pain and that another one in 10 adults is diagnosed with long term pain each year. A recent market research report states that more than 1.5 billion people worldwide suffer from long term pain. In European Union, 49.7 million people reported pain by both its severity and occurrence which included 11.2 million with severe, 29.4 million with moderate and 9.0 million with mild pain.²⁻⁴

More than 650,000 people in the UK have painful o steoarthritis in one or both hips, three fourth people of whom are aged over 65. More than one third of the population aged over 50 have pain at any site that interferes with their normal activities. More than 10 million adults (6 million women and 4 million men) consult their treating doctors each year with arthritis and related conditions. Number of people visiting doctor for musculoskeletal problem is rising each year with age, which is 1 in 10 people aged 15–24 has increased to 1 in 3 people over 75 years of age.⁵

VI.2.2 Summary of treatment benefits

The successful management of pain depends on selecting the proper drug at the correct dosage and balancing effectiveness a gainst s ide effects. For t his reason, t he W orld H ealth Organization introduced the concept of the analgesic ladder. Oral painkillers are usually used as first-line treatment for pain. Initially, painful conditions are treated with painkillers such as paracetamol, aspirin, or NSAIDs. Thereafter, if the pain continues to remain, mild painkillers, such as codeine, and strong painkillers, such as morphine, pethidine, methadone, etc are used in a stepwise manner. Also, new formulations of medicines such as n asal sp rays and under the tongue (sublingual) tablets have increased the options available for pain management.

Ibuprofen works by blocking the action of a substance in the body called cyclo-oxygenase (COX) which is involved in the production of various chemicals in the body, some of which are known as prostaglandins. Prostaglandins are produced in response to injury and certain diseases and conditions,

Risk Management Plan, Version 1.1 Bristol Laboratories Limited Ibuprofen Bril 200 mg, 400 mg and 600 mg Film-coated Tablets.

and cause pain, swelling and inflammation. NSAIDs block the production of these prostaglandins and thereby reduce inflammation and pain. By reducing prostaglandins in the brain, i buprofen lowers body temperature and hence reduces fever. It can also be used to relieve other painful conditions such as headaches, migraine, toothache, nerve pain (neuralgia), period pain muscular pain and pain with stiffness in the joints or muscles.

VI.2.3 Unknowns relating to treatment benefits

Not Applicable

VI.2.4 Summary of safety concerns

Important identified risks

Risk	What is known	Preventability
Side effects r elated to stomach or g ut (gastrointestinal adverse effects)	Ulcers, perforation and bleeding in the stomach or gut have been reported with a ll N SAIDs (medicines u sed to treat pain and inflammation) which may lead to death (fatal).	The m edicinal p roduct s hould not be us ed by patients suffering f rom a n ul cer or bleeding i n t he s tomach or small in testine r elated t o past use of drugs for pain and
	The risk of ulcers, perforation or bleeding in the s tomach or intestines generally increases with higher doses of i buprofen, in p atients w ho ha d	inflammation (NSAIDs) or has had two or more of these episodes in the past.
	ulcers in past or in older patients. The risk also increases if certain other medicines such as NSAIDs (medicines	Simultaneous us e of t he drug product w ith N SAIDs s hould be avoided.
	used f or pain and i nflammation), corticosteroids (medicines used against inflammations), anti-coagulants (blood	Patients who had ulcers in past, should s tart t he t reatment on the lowest dose available.
	thinning m edicines), selective serotonin r euptake inhibitors (medicines to treat low mood), alcohol, bisphosphonates (used i n softening of bones [osteoporosis] and to r educe high blood c alcium levels) and	Patient's hould a void alcohol since it may enhance the side effects of ibuprofen, especially those affecting the stomach and intestines.
	oxpentifylline (used in the treatment of circulatory problems of the arteries of the legs or arms). There are more chances of occurrence of si de ef fects i no lder p eople especially bl eeding a nd p erforation i n	The protective a gents (e.g. misoprostol or proton pump inhibitors) should be given along with ibuprofent othese patients who have high risk of ulcers or bleeding in stomach or intestine.
	the digestive tract, which may be life threatening. Ulcers in stomach and gut, so metimes with bleeding and perforation (holes or abnormal openning), microscopic bleeding from the intestine which may lead to an aemia, passage of dark,	NSAIDs s hould be us ed with care in older patients who are more likely to g et si de effects and are at increased risk of lifethreatening bleeding and ulcers in stomach and gut.
	clotted bl ood i n t he s tool (melaena), gut i nflammation a nd w orsening of inflammation of the large gut (colitis) and d igestive t ract (Crohn's disease) and w orsening of a bnormal pouc h	If t reatment i s co nsidered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used.
	opening from g ut (perforation o r abnormal opening between two organs in the body or between a n or gan a nd the exterior of the body { fistula}) a re	Treatment should be reviewed at regular intervals and stopped if no benefit is seen.
	the co mmon si de e ffects which m ay affect up to 1 in 10 treated people.	Special ca re should be t aken while using NSAIDs in patients

Risk	What is known	Preventability
	Nausea, v omiting, flatulence, diarrhoea, heartburn, a bdominal p ain, indigestion and c onstipation are t he very common si de effects which m ay affect more than 1 in 10 treated people. Digestive t ract u lcer w ith o r w ithout perforation is a common side effect which may affect up to 1 in 10 treated people. Inflammation of stomach (gastritis) is a n uncommon side effect which may affect up to 1 in 100 treated people. Inflammation of the food pipe (oesophagitis), Inflammation of the pancreas, an organ that is important for digestion a nd n arrowing of g ut (intestinal strictures) are very rare side effects which m ay affect up to 1 in 10,000 treated people.	who ha ve s tomach or gut problems like in flammation of the large gu t with ul cers a nd inflammation a ffecting the e digestive t ract as their condition may get worsen.
Heart and blood vessels related side effects (Cardiovascular adverse effects)	Medicines s uch a s i buprofen m ay b e associated with a small increased risk of heart attack (myocardial in farction) or sudden cut off of blood supply to the part of the brain (stroke). The risk is m ore l ikely w ith h igh d oses an d long-term treatment. Fluid r etention, h igh blood pr essure and h eart failure h ave b een r eported with NSAIDs treatment. Unpleasant aw areness of h eart b eat, heart failure, heart attack or high blood pressure a re t he s ide ef fect r eported with v ery r are frequency w hich m ay affect up to 1 in 10,000 treated people.	The m edicinal p roduct s hould not be g iven t o t he pa tients with heart problems. Patient s hould discuss treatment w ith d octor o r pharmacist i f h ave h eart problems, pr evious s troke or might be a tr isk of t hese conditions (for example i f has high blood pressure, high blood sugar [diabetes], or hi gh f at [cholesterol] or is a smoker). Side effects may be minimised by u sing the lo west effective dose f or t he sh ortest d uration necessary to control symptoms.
Allergic reactions (hypersensitivity a nd allergic reactions)	Use of i buprofen t ablets can lead t o allergic reactions in the following patients: Patients with a history of allergy such as of lung problem associated with tightening of a ir passages, making breathing difficult (asthma), runny nose, itchy skin rash or swelling of the lips, face, tongue, or throat after taking medicines containing acetylsalicylic acid, such as aspirin or other medicines for pain and inflammation (called NSAIDs) and in patients a llergic to ibuprofen or any other contents of the	The m edicinal p roduct s hould not be taken by t he pa tients those are allergic to i buprofen or any of the other contents or have h ad allergic r eactions after t aking medicines containing acet ylsalicylic aci d such a s a spirin o r other medicines for p ain and inflammation (called NSAIDs). The m edicinal p roduct s hould be s topped a tt he f irst appearance o f skin r ash, mucosal l esions, or a ny other

Risk	What is known	Preventability
	tablets. The r isk f or de veloping narrowing of t he airways w ith difficulty in breathing (bronchospasm), hives (urticaria) or s welling of t he face, tongue or throat which can cause great d ifficulty in b reathing (angioedema) may be seen in patients suffering from or with a past history of allergies, al lergic cold (hay fever), asthma, l ong t erm sw elling o f n asal mucosa, s inuses, a denoids, or l ong term blockage in respiratory tract.	sign of allergy. Special care should be taken in the cases of allergic conditions.
	The highest risk of these reactions is in the first month of treatment. Allergic reactions su ch as sk in r ash, itching, as thma at tacks (sometimes with low blood pressure) are reported with uncommon frequency which may affect up to 1 in 100 treated persons.	
	Swelling of the face, tongue or throat (larynx) which can cause great difficulty in breathing, rapid heartbeat, severe fall in blood pressure or life threatening shock are reported with very rare frequency which may affect uptolinal notation for the severe forms of skin reactions such as severe rash with blisters on the skin especially on the legs, arms, hands and feet which can also involve the face and lips (erythema multiforme, Stevens-Johnson's syndrome), severe infection with destruction (necrosis) of skin tissue and muscle, hair loss is reported with very rare frequency which may affect up to lin 10,000 treated people.	
Impaired ki dney function (impaired renal function)	In general t he h abitual u se o f painkillers can l ead t o l asting sev ere kidney pr oblems. This r isk may be increased u nder p hysical strain associated with loss of salt and water. Therefore, it should be avoided. Ibuprofen m ay c ause pr oblems w ith kidney function e ven in p atients w ho have not had kidney problems be fore. This may result in swelling of the legs and may e ven lead to he art failure or high blood pressure in susceptible	Before t aking i buprofen, patient should contact doctor if suffering from reduced kidney function. The medicinal product should not be u sed in patients with serious kidney problem. The dose should be kept as low as possible for the shortest duration in the patient with serious kidney problem.

Risk	What is known	Preventability
	individuals. Ibuprofen m ay c ause k idney da mage especially in patients who already have kidney, he art or liver problems, or are taking methotrexate (used to treat cancer), water pills (diuretics) or ACE inhibitors (used for treating high blood pressure), as w ell a s i n t he older people. S topping i buprofen how ever generally leads to recovery.	In case of long term treatment, patients taking t he m edicinal product, e specially h igh r isk patients should be m onitored periodically for kidney function.
	There is a risk of kidney problem in dehydrated (loss of water in the body) children. Kidney pr oblems i ncluding development of swelling c aused by fluid in body 's t issues (oedema), inflammation of the k idneys a nd kidney f ailure a re uncommon s ide effects reported, which may affect up to 1 in 100 treated people.	
Increased r isk o f bleeding	Ibuprofen m ay temporarily block the action of blood clotting cells (platelet aggregation) and increase the bleeding time.	The m edicinal p roduct s hould not be g iven t o t he pa tients having a ctive bl eeding (including in the brain).
	NSAIDs should not be combined with ticlopidine (a bl ood thinning medicines) due to i ncreased r isk of bleeding.	Patients with bleeding problem or on medicines t o p revent clotting of bl ood should be observed carefully.
	NSAIDs may i ncrease t he ef fects o f anticoagulants, s uch a s warfarin or heparin.	Patients with brain dysfunction should only be t reated with ibuprofen af ter car eful consideration.
		In case o f si multaneous treatment with w arfarin o r heparin or t iclopidine bleeding time should be monitored.
Use during last 3 months of pregnancy use during late pregnancy	Ibuprofen must not be taken during the last 3 m onths o f p regnancy si nce i t may cau se m ajor h eart, l ung an d kidney problems in the unborn child.	The m edicinal product s hould not be g iven during last 3 months of pregnancy.
	If used at the end of pregnancy, it may cause b leeding t endencies i n b oth mother a nd c hild a nd weaken t he strength of u terine c ontractions thus delaying the onset of delivery.	
Headache because o f	Long t erm use of a ny t ype o f	If t his situation is ex perienced

Risk	What is known	Preventability
long t erm us e of medicine (medication overuse headache)	painkillers for h eadaches can m ake them w orse (medication o veruse headache). Headache is the common (may affect up to 1 in 10 treated people) side effect reported with use of ibuprofen.	or su spected, ad vice of do ctor should be ob tained a nd treatment should be stopped. Medication o veruse h eadache (MOH) is suspected in patients who ha ve f requent o r daily headaches d espite (or b ecause of) the regular use of medicines used to treat headache.

Important potential risks

Risk	What is known
Female fertility	This medicine belongs to class of NSAIDs which can affect fertility in women. The effect on fertility is r eversible on s topping the medicine. In situation where p regnancy is planned or there is problem in becoming pregnant, this medicine may not be taken.
Use during first 6 months of pregnancy (use during early pregnancy)	The drug product should be used in the first 6 months of pregnancy after consulting doctor and only when clearly necessary. If the drug product is used by women during first six months of her pregnancy, the dose should be kept low and duration of treatment as short as possible.
Off-label use of simultaneous NSAIDs (Off-label use of concomitant NSAIDs)	Off-label use is the unapproved use of a medicine other than the specified use. Simultaneous use of various NSAIDs can increase the risk of ulcers and bleeding in the stomach and gut. Patients s hould no t us e ibuprofen simultaneously with other NSAIDs.

Missing information

Risk	What is known
None	

VI.2.5 Summary of risk minimisation measures by safety concern

All medicines have a Summary of Product Characteristics (SPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the

Risk Management Plan, Version 1.1 Bristol Laboratories Limited Ibuprofen Bril 200 mg, 400 mg and 600 mg Film-coated Tablets.

risks and recommendations f or m inimising t hem. A n ab breviated v ersion o f this i n lay language i s pr ovided i n the f orm o f t he p ackage l eaflet (PL). The m easures i n these documents are known as routine risk minimisation measures.

The Summary of Product Characteristics and the Package leaflet for Ibuprofen can be found in the Ibuprofen's EPAR page.

This medicine has no additional risk minimisation measures.

VI.2.6 Planned post authorisation development plan

Not applicable

VI.2.7 Summary of changes to the risk management plan over time

This is the first risk management plan for Ibuprofen 200 mg, 400 mg and 600 mg film-coated tablets.